COST-UTILITY ANALYSIS OF ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR SACUBITRIL/VALSARTAN COMPARED WITH ACE INHIBITORS FOR THE TREATMENT OF CHRONIC HEART FAILURE IN THE UNITED STATES

被引：0

作者：

Harrington, R. L. ^{[1
]}

Zueger, P. M. ^{[1
]}

Kumar, V. M. ^{[1
]}

Rigoni, G. ^{[1
]}

Atwood, A. M. ^{[1
]}

DiDomenico, R. J. ^{[1
]}

Touchette, D. R. ^{[1
]}

机构：

[1] Univ Illinois, Chicago, IL USA

来源：

VALUE IN HEALTH | 2016年 / 19卷 / 03期

关键词：

D O I：

10.1016/j.jval.2016.03.120

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCV55

引用

页码：A49 / A49

页数：1

共 50 条

[1] COST-UTILITY ANALYSIS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF CHRONIC HEART FAILURE IN GREECE
Stafylas, P.
Farmakis, D.
Kourlaba, G.
Giamouzis, G.
Chatzikou, M.
Kossiva, E.
Maniadakis, N.
Parissis, J.
VALUE IN HEALTH, 2016, 19 (07) : A654 - A654
[2] Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
Cho, In-Jeong
Kang, Seok-Min
KIDNEY RESEARCH AND CLINICAL PRACTICE, 2021, 40 (04) : 555 - 565
[3] Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
Krittayaphong, Rungroj
Permsuwan, Unchalee
CLINICAL DRUG INVESTIGATION, 2021, 41 (10) : 907 - 915
[4] Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
Rungroj Krittayaphong
Unchalee Permsuwan
Clinical Drug Investigation, 2021, 41 : 907 - 915
[5] Effects of the angiotensin receptor-neprilysin inhibitor/sacubitril-valsartan administration on quality of life and outcome in heart failure with reduced ejection fraction: a meta analysis
Dewi, Kadek Intan Murti
Pintaningrum, Yusra
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0F)
[6] Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
Choi, Hong-Mi
Shin, Mi-Seung
KOREAN JOURNAL OF INTERNAL MEDICINE, 2020, 35 (03): : 498 - 513
[7] Six months clinical and echocardiographic outcome of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) therapy in heart failure patients with reduced ejection fraction
Alnims, M. Mohammed
Magdy, Abdelhamid
Meguid, M. Abdel
Ahmed, Shehata
EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 101 - 102
[8] Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
Bratsos, Sosipatros
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (01)
[9] Is there a place for angiotensin receptor-neprilysin inhibitors in the treatment of heart failure patients after heart transplantation?
Gulin, Dario
Planinic, Zrinka
Habek, Jasna Cerkez
Sikic, Jozica
INDIAN JOURNAL OF PHARMACOLOGY, 2019, 51 (06) : 413 - 415
[10] LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
Martin P Lefkowitz
BMC Pharmacology and Toxicology, 16 (Suppl 1)

← 1 2 3 4 5 →